2019 US Medicinal Products
Financial Strength Rankings using Artificial Intelligence
Top rated | 12 of 50 |
Best rating | 159 % |
Worst rating | -420 % |
New companies | 6 |
Negative Economic Capital Ratio | 16 of 50 |
Financial Strength Rankings using Artificial Intelligence
Top rated | 12 of 50 |
Best rating | 159 % |
Worst rating | -420 % |
New companies | 6 |
Negative Economic Capital Ratio | 16 of 50 |
TAURIGA SCIENCES INC. climbed 22 positions from 47 to 25 due to its excellent Net Income.Navidea Biopharmaceuticals Inc. lost 45 positions from 1 to 46 due to its bad Net Income.Huntsman CORP entered the 2019 ranking at rank 19, making it the best newcomer.
Revenues | 41.6 B |
Assets | 55.1 B |
Expenses | 38.6 B |
Stockholders Equity | 22.6 B |
Unprofitable Companies | 28 of 50 |
Photo source: https://openai.com/dall-e-3/ RealRate is excited to announce that the new 2024 [...]
We are extremely excited to announce that an interview with Holger Bartel has [...]
On February 14th, 2024, something momentous happened. Nvidia, the chip and graphics card [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Pharma are [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Savings are [...]
Source: https://openai.com/dall-e-3/ The results for RealRate’s 2023 ranking for U.S. Chemicals are [...]
Source: https://openai.com/dall-e-3/ The machines have emerged and the results for RealRate’s 2023 [...]
Source: https://openai.com/dall-e-2/ The results for RealRate’s 2023 ranking for U.S. Medicinal Products [...]
This year's rating information is fee-based. Please request rates at
james.woods@realrate.ai